$32.4 M

ATNM Mkt cap, 27-Mar-2020
Actinium Pharmaceuticals Net income (Q3, 2019)-6.6 M
Actinium Pharmaceuticals EBIT (Q3, 2019)-6.7 M
Actinium Pharmaceuticals Cash, 30-Sept-201914.3 M
Actinium Pharmaceuticals EV18.2 M

Actinium Pharmaceuticals Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

Cost of goods sold

Gross profit

R&D expense

3.4m2.7m12.3m13.3m17.5m17.7m17.1m

General and administrative expense

337.04.5m3.9m10.2m11.5m9.3m9.2m6.7m

Operating expense total

10.0k7.9m6.6m22.4m24.8m26.8m26.9m23.8m

Depreciation and amortization

1.6k53.5k77.5k55.9k

EBIT

(10.0k)(7.9m)(6.6m)(22.5m)(24.8m)(26.8m)(26.9m)(23.8m)

Interest expense

4.8k1.1m4.2m866.03.8m2.5m309.6k173.4k

Investment income

5.4k

Income tax expense

Net Income

10.3k(8.4m)(10.8m)(24.7m)(21.0m)(24.3m)(26.6m)(23.7m)

Actinium Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

150.05.6m5.5m6.7m25.6m20.5m17.4m

Accounts Receivable

2.1b

Prepaid Expenses

167.1k218.4k699.9k803.5k

Inventories

1.8m

Current Assets

150.05.8m5.8m7.4m26.5m22.4m17.8m

PP&E

3.0k13.9k127.7k106.1k88.5k57.4k

Total Assets

150.05.8m5.8m7.6m26.6m22.5m18.3m

Accounts Payable

6.0897.0k379.0k2.3m1.5m4.2m4.6m

Short-term debt

140.0k157.8k283.6k265.7k

Current Liabilities

26.3k4.6m7.3m9.5m4.6m4.5m4.7m

Long-term debt

34.7k

Total Debt

140.0k315.7k567.1k531.4k249.2k

Total Liabilities

84.5k7.3m9.5m4.6m4.5m4.7m

Common Stock

111.6k213.9k24.6k30.0k44.1k

Preferred Stock

Additional Paid-in Capital

63.9k56.7m64.9m89.3m134.2m154.5m176.7m

Retained Earnings

(259.8k)55.7m(91.2m)(112.2m)(136.6m)(163.2m)

Total Equity

(84.3k)(1.1m)(1.6m)(1.9m)22.0m18.0m13.7m

Debt to Equity Ratio

-0.2 x-0.3 x0 x

Debt to Assets Ratio

0.1 x0.1 x0 x

Financial Leverage

0 x-5.1 x-3.7 x-3.9 x1.2 x1.3 x1.3 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

150.0150.0150.0142.03.2m5.7m4.0m5.9m14.7m11.8m19.3m26.0m24.8m22.2m20.5m15.5m17.1m11.5m20.5m26.8m21.5m14.8m9.9m19.5m14.3m

Prepaid Expenses

117.1k84.3k53.0k667.9k608.1k671.9k634.0k257.5k157.6k937.1k922.7k1.6m1.0m1.0m673.0k299.6k336.2k189.9k

Inventories

Current Assets

150.0150.0150.0142.03.4m5.7m4.0m6.5m15.3m12.4m19.9m26.2m24.9m23.2m21.4m17.1m18.1m12.5m21.2m27.6m22.1m15.2m10.3m19.9m14.6m

PP&E

158.6k158.6k6.9k14.2k132.9k141.0k101.4k86.2k95.3k115.6k110.0k91.2k75.9k70.0k65.7k140.2k134.8k121.1k

Total Assets

150.0150.0150.0142.03.4m5.7m4.0m6.6m15.4m12.6m20.1m26.3m25.0m23.3m21.6m17.3m18.2m13.0m21.7m28.1m22.6m15.7m12.2m21.8m16.3m

Accounts Payable

1.5k6.0459.9k793.6k312.0k615.3k1.0m1.7m1.2m1.0m888.5k1.9m1.4m2.6m4.8m3.6m3.5m6.4m5.3m4.1m5.3m4.7m5.1m

Short-term debt

74.7k37.0k94.5k55.0k189.8k92.3k178.1k89.6k175.4k100.8k25.3k

Current Liabilities

24.6k28.1k29.9k29.2k31.1k2.8m3.8m3.4m20.0m11.1m10.2m3.6m3.1m2.2m3.3m2.5m3.0m5.4m4.1m3.5m6.4m5.3m4.1m5.9m5.2m5.5m

Long-term debt

34.7k

Total Debt

74.7k37.0k189.0k109.9k224.5k184.5k356.2k179.1k175.4k100.8k25.3k

Total Liabilities

78.3k81.8k94.1k100.4k104.0k3.8m3.4m11.1m10.2m3.6m3.1m2.2m3.3m2.5m3.0m5.4m4.1m3.5m6.4m5.3m4.1m6.9m6.1m6.4m

Common Stock

111.6k111.6k111.6k111.6k111.6k213.9k235.8k236.6k25.6k27.6k29.6k35.7k40.5k41.9k44.9k47.3k47.7k57.2k58.5k80.0k119.1k162.0k164.7k

Preferred Stock

Additional Paid-in Capital

63.9k63.9k63.9k63.9k63.9k56.8m60.9m61.0m69.7m84.0m88.1m110.7m125.0m128.5m136.6m142.3m144.0m157.4m160.5m176.1m191.1m191.6m192.0m197.8m213.1m213.9m

Retained Earnings

(253.6k)(257.1k)(269.4k)(275.7k)(279.4k)56.4m59.2m60.6m(797.0m)(85.8m)(94.3m)(101.7m)(105.7m)(116.6m)(123.3m)(129.9m)(144.6m)(151.7m)(158.0m)(169.5m)(174.4m)(180.5m)(192.5m)(197.6m)(204.2m)

Total Equity

(78.2k)(81.7k)(94.0k)(100.3k)(104.0k)550.8k1.9m604.3k(13.5m)4.3m2.4m16.4m23.3m22.9m20.1m19.1m14.2m12.9m8.9m18.2m21.7m17.3m11.6m5.3m15.7m9.9m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x

Financial Leverage

0 x0 x0 x0 x6.1 x3 x6.7 x-0.5 x3.6 x5.3 x1.2 x1.1 x1.1 x1.2 x1.1 x1.2 x1.4 x1.5 x1.2 x1.3 x1.3 x1.4 x2.3 x1.4 x1.6 x

Actinium Pharmaceuticals Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

10.3k(8.4m)(10.8m)(24.7m)(21.0m)(24.3m)(26.6m)(23.7m)

Depreciation and Amortization

581.01.6k37.9k53.5k77.5k55.9k50.7k

Accounts Payable

(13.7k)334.3k(518.1k)1.9m(793.9k)2.7m405.2k1.1m

Cash From Operating Activities

539.0(5.2m)(6.3m)(14.3m)(18.5m)(20.8m)(21.6m)(20.6m)

Purchases of PP&E

(2.4k)(16.6k)(151.7k)(47.8k)(60.0k)(24.7k)(96.1k)

Cash From Investing Activities

(2.4k)(16.6k)(186.4k)(47.8k)(109.8k)(380.9k)(96.1k)

Short-term Borrowings

(140.0k)(161.8k)(283.6k)(265.7k)

Cash From Financing Activities

(539.0)5.1m6.2m15.7m37.5m15.8m18.8m17.0m

Net Change in Cash

(85.1k)(85.3k)1.2m18.9m(5.1m)(3.1m)(3.7m)

Interest Paid

561.0866.07.9k5.0k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

16.5k12.9k(9.6k)(15.9k)(19.7k)(689.0k)(3.5m)(4.9m)(16.7m)(13.2m)(19.3m)(3.1m)(10.5m)(14.5m)(4.4m)(11.0m)(17.6m)(8.1m)(15.1m)(21.4m)(6.3m)(11.2m)(17.3m)(5.7m)(10.7m)(17.3m)

Depreciation and Amortization

1.4k9.5k23.8k10.4k26.6k43.4k18.1k37.6k57.7k20.9k35.3k46.3k12.0k24.8k38.1k103.9k209.1k315.7k

Accounts Payable

(13.7k)(12.2k)1.0k(437.1k)(103.4k)(585.0k)236.3k666.5k1.4m(1.0m)(1.3m)(1.4m)378.9k(94.8k)1.1m573.9k(590.3k)(744.8k)620.5k616.1k(527.9k)(493.4k)(1.1m)(680.6k)

Cash From Operating Activities

5.0k5.0k(6.0k)(13.1k)(2.3m)(3.3m)(4.9m)(2.5m)(5.1m)(9.3m)(5.8m)(11.1m)(14.6m)(4.8m)(11.0m)(16.5m)(5.4m)(12.5m)(18.4m)(5.5m)(9.7m)(16.3m)(5.5m)(10.9m)(16.5m)

Purchases of PP&E

(1.1k)(1.1k)(8.0k)(1.7k)(128.4k)(150.9k)(959.0)(26.9k)(27.6k)(41.5k)(42.7k)(8.3k)(16.7k)(23.5k)(7.0k)(26.8k)(85.5k)(51.1k)(59.5k)(59.5k)

Cash From Investing Activities

(25.0k)(25.0k)(1.1k)(1.1k)(8.0k)(1.7k)(128.4k)(150.9k)(959.0)(26.9k)(77.4k)(91.3k)(92.6k)26.4k(372.8k)(379.6k)(7.0k)(26.8k)(85.5k)(51.1k)(59.5k)(59.5k)

Short-term Borrowings

(65.3k)(103.0k)(140.0k)(63.3k)(102.9k)(157.8k)(93.8k)(191.3k)(283.6k)(87.6k)(176.1k)(265.7k)(73.8k)(148.5k)(223.9k)

Long-term Borrowings

(17.6k)(35.6k)(54.0k)

Cash From Financing Activities

20.0k20.0k6.0k13.1k(65.3k)3.4m3.3m2.8m14.3m15.7m18.4m30.3m32.7m1.4m5.9m6.5m1.9m3.8m18.8m14.9m13.8m13.8m1.8m16.8m17.2m

Net Change in Cash

(8.0)(2.4m)31.7k(1.6m)344.4k9.1m6.2m12.6m19.2m18.1m(3.4m)(5.2m)(10.1m)(3.4m)(9.1m)22.7k9.4m4.1m(2.6m)(3.7m)5.9m647.6k

Interest Paid

5.7k7.3k7.9k2.7k4.3k5.0k2.4k4.1k4.9k

Income Taxes Paid

561.0561.0561.0

Actinium Pharmaceuticals Ratios

USDY, 2019

EV/EBIT

-2.7 x

EV/CFO

-1.1 x

Financial Leverage

1.6 x